Trinity Biotech Receivables 2010-2024 | TRIB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Trinity Biotech receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Trinity Biotech receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$202.2B
Stryker (SYK)	$143.3B
Boston Scientific (BSX)	$130.1B
Medtronic (MDT)	$112.5B
EssilorLuxottica (ESLOY)	$111.7B
Lonza Group Ag (LZAGY)	$45.4B
Haleon (HLN)	$43.5B
GE HealthCare Technologies (GEHC)	$39.3B
ResMed (RMD)	$37B
Terumo (TRUMY)	$29.6B
Koninklijke Philips (PHG)	$25B
Zimmer Biomet Holdings (ZBH)	$21.5B
Insulet (PODD)	$18.8B
Baxter (BAX)	$17.7B
Smith & Nephew SNATS (SNN)	$10.6B
Bio-Rad Laboratories (BIO)	$10.3B
BellRing Brands (BRBR)	$9.1B
Demant (WILYY)	$8.4B
Lantheus Holdings (LNTH)	$6.1B
Haemonetics (HAE)	$4.5B
TG Therapeutics (TGTX)	$4.5B
ICU Medical (ICUI)	$4.3B
Prestige Consumer Healthcare (PBH)	$4B
Perrigo (PRGO)	$3.6B
Neogen (NEOG)	$3.5B
Envista Holdings (NVST)	$3.5B
Agios Pharmaceuticals (AGIO)	$3.4B
GN Store Nord (GNNDY)	$3B
Shandong Weigao Medical Polymer (SHWGF)	$3B
QuidelOrtho (QDEL)	$2.9B